Eculizumab (Anti-Complement C5)

Product Name：Eculizumab biosimilar

CAS No.:    219685-50-4                                              

Molecular Weight： 148 kDa                    

Type:    Whole antibody                     

Target：  Complement protein C5
Antibody Form:  Purified immunoglobulin
Physical Form:  Solution
Storage:  -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
Description

Eculizumab biosimilar is a recombinant humanized monoclonal IgG2/4κ antibody produced by Chinese hamster ovary cell culture and purified by standard bioprocess technology. Eculizumab biosimilar contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculiz umab biosimilaris composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.

Biological Activity
Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.

For research use only.Not for use in humans